Immune Profiles Elicited by Different HBV Vaccine Modalities and Their Associations with Serological and Intrahepatic Viral Outcomes.

Huiying Xiao, Jinhang He, Lili Zhu, Songmei Wang, Chao Qiu, Xuanyi Wang

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Huiying XiaoInstitutes of Biomedical Sciences, Fudan University, Shanghai 200032, China.

Jinhang HeShanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai 200032, China.

Lili ZhuInstitutes of Biomedical Sciences, Fudan University, Shanghai 200032, China.

Songmei WangLaboratory of Medical Molecular Biology, Experimental Teaching Center, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.

Chao QiuInstitutes of Biomedical Sciences, Fudan University, Shanghai 200032, China.ORCID 0000-0001-9401-5219

Xuanyi WangInstitutes of Biomedical Sciences, Fudan University, Shanghai 200032, China.ORCID 0000-0001-6398-9184

Funding

National Natural Science Foundation of China 82172253, 31872744

6 · The paper itself

Abstract

Therapeutic vaccination for chronic hepatitis B aims to restore HBV-specific T-cell immunity and contribute to a functional cure. We systematically compared the immune profiles and antiviral efficacy of four vaccine modalities: recombinant HBsAg (rHBsAg), antigen-antibody immune complex (IC), a DNA vaccine encoding HBsAg (DNA-HBsAg), and an HBsAg-Fc fusion DNA vaccine (DNA-HBsAg-Fc). In naïve mice, the rHBsAg vaccine predominantly induced anti-HBs IgG responses, whereas the IC vaccine elicited strong anti-HBs IgG and detectable CD4

Indexed as

Hepatitis BHepatitis B VaccinesHepatitis B virusLiverAnimalsAntigen-Antibody ComplexCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFemaleHepatitis B AntibodiesHepatitis B Surface AntigensHumansImmunoglobulin GMiceVaccines, DNAAntigen-Antibody ComplexHepatitis B AntibodiesHepatitis B Surface AntigensHepatitis B VaccinesImmunoglobulin GVaccines, DNAantigen–antibody immune complexCD8+ T-cell responsesDNA vaccineshepatitis B virus

Identifiers

PMID42883747

DOI10.3390/ijms27198499

PMCPMC13664768

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.